Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPR–Cas9 gene editing technology. The company went public on 2 Feb 2016. This initial public offering was noted as being the first such from a company which aims to use "DNA itself to internally treat afflictions". The company has conceded that “It will be many years, if ever, before we have a product candidate ready for commercialization.” Further, the companys valuation depends on a single patent, which holder was in dispute as of early 2016, presenting a major risk to the companys continued viability. The company entered into a strategic collaboration with Juno Therapeutics in 2015 to combine its CRISPR-Cas9 technology with Junos experience in creating chimeric antigen receptor and high-affinity T cell receptor therapeutics to the end of developing cancer therapeutics. The company announced in 2015 that it was planning a clinical trial in 2017 using CRISPR gene editing techniques to treat Lebers congenital amaurosis, a rare genetic illness that causes blindness.
Highest paying job titles at Editas Medicine include Clinical Director, Director of Regulatory Affairs, and Scientist